EPIX vs. AQST, SEPN, ITOS, DSGN, TERN, SLRN, CRDF, URGN, AVIR, and IMMP
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Aquestive Therapeutics (AQST), Septerna (SEPN), iTeos Therapeutics (ITOS), Design Therapeutics (DSGN), Terns Pharmaceuticals (TERN), Acelyrin (SLRN), Cardiff Oncology (CRDF), UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
ESSA Pharma vs.
ESSA Pharma (NASDAQ:EPIX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
In the previous week, ESSA Pharma had 9 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 13 mentions for ESSA Pharma and 4 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.38 beat ESSA Pharma's score of 0.19 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.
75.1% of ESSA Pharma shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 15.5% of ESSA Pharma shares are held by insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ESSA Pharma has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat ESSA Pharma's return on equity.
ESSA Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500.
ESSA Pharma currently has a consensus target price of $9.50, suggesting a potential upside of 508.97%. Aquestive Therapeutics has a consensus target price of $10.57, suggesting a potential upside of 250.05%. Given ESSA Pharma's higher possible upside, equities research analysts plainly believe ESSA Pharma is more favorable than Aquestive Therapeutics.
ESSA Pharma received 134 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 68.25% of users gave Aquestive Therapeutics an outperform vote.
Aquestive Therapeutics has higher revenue and earnings than ESSA Pharma. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
ESSA Pharma and Aquestive Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:EPIX) was last updated on 3/29/2025 by MarketBeat.com Staff
